DMT patents
1 | Owner/Applicant | Patent/Pub. No. | Title | Priority Date | Status | General subject matter | |
|---|---|---|---|---|---|---|---|
2 | 1 | Gligamesh Pharmaceuticals | WO2021168082A1 | Specific tryptamines for use in the treatment of mood disorders | 2020-02-18 | Published | Tryptamines for mood disorders; disclosing many and in vitro/in vivo data for four: N-methyl-N-ethyltryptamine, N-ethyl- N-propyltryptamine, and 5-fluoro analogs |
3 | 2 | Yale University, U.S. Dep't of Veterans Affairs | US20210236523A1 | Psychedelic treatment for headache disorders | 2020-02-05 | Pending in US | Treating a headache disorder by administering psilocybin, LSD, mescaline, DMT, DOI, DOB, and analogs thereof |
4 | 3 | Synbionik Gmbh | WO2021110992A1 | Non-naturally occurring bacteria modified able to produce tryptophan derived compounds | 2019-12-04 | Published | Non-naturally occurring microorganism modified to produce N,N-DMT and 5-MeO-DMT; methods of purifying it and formulating into pharmaceutical compositions |
5 | 4 | Intima Bioscience | WO2021067626A1 | Genetic engineering of fungi to modulate tryptamine expression | 2019-10-01 | Published | Methods for modulating the tryptamine biosynthesis pathway and genetically modified organisms with induced and/or increased expression of tryptamines, including DMT |
6 | 5 | CaaMTech | US20210023052A1 | Compositions containing toad secretion compounds | 2020-07-23 | Pending in US | Compositions of (1) a purified toad secretion tryptamine, including N,N-DMT and 5-MeO-DMT, and (2) a serotonergic drug, psilocybin derivative, cannabinoid, or terpene |
7 | 6 | Danmarks Tekniske Universitet | WO2021052989A1 | Yeast cells and methods for production of tryptophan derivatives | 2019-09-15 | Published | Transformed cells capable of producing compounds including halogenated N,N-DMT, and methods of their use in production |
8 | 7 | University of Maryland | WO2021030571A1 | Methods of Treating Psychological and Brain Disorders | 2019-08-12 | Published | Methods of treating a psychological disorder by administering a 5-HT agonist in combination with a 5-HT2A antagonist, the 5-HT agonists including DMT |
9 | 8 | Applied Biology Inc | US20210030787A1 | Methods for protecting hair follicles | 2019-07-31 | Pending in US | Topical agents for reducing and inhibiting the effects of hair loss and hair shedding due to chemotherapy and radiotherapy, including by additionally using N,N-DMT |
10 | 9 | Concept Matrix Solutions | US20210015833A1 | Oral soft gel capsule containing psychedelic compound | 2019-07-18 | Pending in US | Softgels containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations" |
11 | 10 | Concept Matrix Solutions | US20210015738A1 | Oral dissolvable film containing psychedelic compound | 2019-07-17 | Pending in US | Films containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations" |
12 | 11 | GH Research Limited | WO2020254584A1 | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) in methyl tert.-butyl ether (mtbe) and less than 5 wt% of an aliphatic anti-solvent | 2019-06-19 | Published | Metholds of purifying 5-MeO-DMT and producing crystalline 5-MeO-DMT; compositions of purified 5-MeO-DMT |
13 | 12 | Small Pharma Ltd | WO2021116503A2 | Deuterated compounds | 2019-06-03 | Published | Deuterated N,N-DMT compounds and compositions, their use to treat psychiatric or neurological disorders, and their synthesis |
14 | 13 | Small Pharma Ltd | WO2020245133A1 | Therapeutic Compositions Comprising Deuterated Or Partially Deuterated N,N-dimethyltryptamine Compounds | 2019-06-03 | Published | Compositions comprising two or more of N,N-DMT and deuterated N,N-DMT compounds, their use to treat psychocognitive disorders, and their preparation |
15 | 14 | Karl Dresdner, Michael Cary, Chase Hudson | US20200345585A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | 2019-04-30 | Pending in US | Processes for making aqueous therapeutic nanoparticles, including with substituted tryptamines to treat depression, anxiety and PTSD, including N,N-DMT and 5-MeO-DMT |
16 | 15 | The Regents Of The University Of California | WO2020185581A2 | Compositions And Methods For Modulating Lipid And Steroid Metabolism | 2019-03-08 | Published | Methods for promoting colonization of spore-forming bacteria in a patient’s gut, comprising administering a serotonin receptor agonist, including N,N-DMT and 5-MeO-DMT |
17 | 16 | University Of Padova, Institute For Research In Biomedicine, Barcelona | WO2020181194A1 | Compositions And Methods Of Use Comprising Substances With Neural Plasticity Actions Administered At Non-psychedelic/psychotomimetic Dosages And Formulations | 2019-03-07 | Published | Structural analogues to psilocin, norpsilocin, psilocybin, baeocystin, norbaeocystin, and N,N-DMT, and their use as neuroplastogens and for microdosing |
18 | 17 | GH Research Limited | WO2020169851A1 | Compositions Comprising 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) For Use In Treating Mental Disorders | 2019-02-22 | Published | 5-MeO-DMT for treatment of MDD where administered via intravenous, intramuscular or subcutaneous route |
19 | 18 | GH Research Limited | WO2020169850A1 | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) For Treating Depression | 2019-02-22 | Published | 5-MeO-DMT for treatment of MDD where administered via inhalation |
20 | 19 | University of North Carolina at Chapel Hill | US20200187851A1 | Periodontal disease stratification and uses thereof | 2018-12-17 | Pending in US | Methods of treating and preventing periodontal disease and tooth loss, by administering a therapeutic agent, including 5-MeO-DMT |
21 | 20 | Palo Alto Investors LP | US20200179349A1 | Methods of Treating Food Allergy Conditions | 2018-12-06 | Pending in US | Treating a food allergy condition by administration of a psychedelic, including N,N-DMT and 5-MeO-DMT |
22 | 21 | Neurolign USA | WO2020097320A1 | Rehabilitation Of Subjects With Pharmacologically Induced Neuroplasticity | 2018-11-08 | Published | "Neurological rehabilitation method" comprising performing tasks "during periods of pharmacologically induced neuroplasticity" including by administration of DMT |
23 | 22 | Rejoy | US20200060997A1 | TARR Receptor Agonists For Sexual Dysfunction | 2018-08-27 | Pending in US | Compositions of a TARR receptor agonist for treating female sexual dysfunction, where it is applied to contract smooth muscle of the nipple areola complex, including of N,N-DMT |
24 | 23 | Yale University, U.S. Dep't of Veterans Affairs | WO2020041329A1 | Combination therapy for treating or preventing depression or other mood diseases | 2018-08-20 | Published | Treating depression and mood disorders, with combination of a TOR inhibitor or immunosuppressant together with ketamine, psilocybin, LSD, ayahuasca, and DMT |
25 | 24 | Applied Biology, Inc. | WO2020023084A1 | Taar Receptor Agonists For The Treatment Of Alopecia | 2018-07-26 | Published | Methods for treating hair shedding by applying a composition of a pilomotor effective amount of a Taar receptor agonist topically, including N,N-DMT |
26 | 25 | Robert John Petcavich | WO2019246532A1 | Method Of Inducing Dendritic And Synaptic Genesis In Neurodegenerative Chronic Diseases | 2018-06-21 | Published | Methods of inducing neuron dendritic and synaptic genesis in neurodegenerative diseases by administering a tryptamine including N,N-DMT and 5-MeO-DMT |
27 | 26 | Anavex Life Sciences Corp. | WO2019222754A1 | Optimized Sigma-1 Agonist Method Of Responder Selection And Treatment | 2018-05-18 | Published | Methods of selecting a subject having a genetic polymorphism causing the subject to have an altered response to a Sigma-1 receptor agonist, including where the agonist is DMT |
28 | 27 | New Atlas Biotechnologies LLC | US20210108238A1 | Processes For The Production Of Tryptamines | 2018-03-08 | Pending in US | Prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamines, including N,N-DMT and 5-MeO-DMT |
29 | 28 | Akili Interactive Labs | WO2019161050A1 | Cognitive Platform Including Computerized Elements Coupled With A Therapy For Mood Disorder | 2018-02-18 | Published | Computer-implemented systems and methods for mood and cognitive assessment and treatment, including during psychedelic-assisted therapy with DMT |
30 | 29 | Consejo Superior De Investigaciones Científicas (CSIC) | WO2019081764A1 | Combination Product For The Treatment Of Neurological And/or Psychiatric Disorders | 2017-10-26 | Published | Combination product comprising (1) psychedelic, including N,N-DMT and 5-MeO-DMT, and (2) a 5-HT2A receptor antagonist to prevent hallucinations |
31 | 30 | Eleusis | WO2019079742A1 | Methods and systems for enhancing safety of psychedelic drug therapies | 2017-10-19 | Published | Screening a candidate for treatment with psychedelic agent, including 5-MeO-DMT |
32 | 31 | GW Research Ltd | US20200237683A1 | Use Of Cannabidiol In Combination With 5-ht2b Receptor Agonists Or Amphetamins In The Treatment Of Epilepsy | 2017-09-29 | Pending in US | CBD in combination with a 5-HT2B receptor agonist to treat epilepsy, including N,N-DMT and 5-MeO-DMT |
33 | 32 | Bar-Ilan University, Ramot at Tel Aviv University | US20200061076A1 | Methods Of Treating Leukodystrophies | 2017-05-11 | Pending in US | Methods of treating leukodystrophy by administering an agent participating in Sigma-1 Receptor signaling pathway, including DMT |
34 | 33 | Eleusis | US20200147038A1 | Assessing and treating psychedelic-responsive subjects | 2017-04-20 | Pending in US | Improving mental or physical well-being by administration of a psychedelic, including 5-MeO-DMT |
35 | 34 | The Regents Of The University Of California | US20200030309A1 | Compounds For Increasing Neural Plasticity | 2016-09-29 | Pending in US | Methods for increasing neural plasticity by contacting a neuronal cell with a non-hallucinogenic analog of a psychedelic compound, including analogs of DMT |
36 | 35 | Paul Stamets | US20180021326A1 | Compositions and methods for enhancing neuro- regeneration and cognition by combining mushroom extracts containing [] psilocin or psilocybin with erinacines or hericenones enhanced with niacin | 2016-07-23 | Abandoned | Compositions of niacin and mushroom or cannabis extracts, together with compounds including N,N-DMT and 5-MeO-DMT, and their use to improve neurological health |
37 | 36 | Paul Stamets | US20200375967 | Compositions of psilocybin and analogs | 2016-07-23 | Pending in US | Compositions of niacin and mushroom or cannabis extracts, together with compounds including N,N-DMT and 5-MeO-DMT, and their use to improve neurological health |
38 | 37 | Philip Morris Products | US10750785B2 | Aerosol-generating system comprising a bimetallic strip | 2015-03-27 | Granted 2020-08-25 (expires 2037-02-21) | Vaporizer systems for delivery of a medicament, including N,N-DMT and 5-MeO-DMT |
39 | 38 | Teva Pharmaceuticals | WO2016138135A1 | Sigma-1 Receptor Modulators For Treating Huntington's Disease | 2015-02-25 | Published | Methods of treating neurodegenerative diseases by administering a Sigma-1 receptor modulator, including N,N-DMT |
40 | 39 | Syqe Medical | US10118006B2 | Methods, devices and systems for pulmonary delivery of active agents | 2014-06-30 | Granted 2018-11-06 (expires 2035-06-30) | Metered dose inhalers that monitor effects and their use to deliver pharmaceutically active agents including cannabinoids, salvinorin A, cocaine, psilocybin, and DMT |
41 | 40 | Philip Morris Products | US10721963B2 | Electrically heated aerosol delivery system | 2013-05-21 | Granted 2020-07-28 (expires 2036-11-30) | Vaporizer devices and cartridges for delivering an aerosolised medicament, including N,N-DMT and 5-MeO-DMT |
42 | 41 | ALS Mountain LLC | US20140350064A1 | Pharmaceutical Composition Comprising An Ampk Activator And A Serotonergic Agent And Methods Of Use Thereof | 2013-03-15 | Abandoned | Pharmaceutical compositions of a AMPK activator and a serotonergic agent, the serotonergic agent including N,N-DMT and 5-MeO-DMT |
43 | 42 | Harvard College, NIH | US20140221499A1 | Novel rodent control agents and uses thereof | 2011-06-16 | Abandoned | Methods for controlling rodents by contacting the rodents with a compound which is a ligand for an olfactory TAAR receptor, including 5-MeO-DMT |
44 | 43 | Syqe Medical | US11071712B2 | Method and system for drug delivery | 2010-12-22 | Granted 2021-07-27 | Drug dose structure for use with an inhaler device having source material from which at least one active substance is released for delivery by vaporization, including DMT |
45 | 44 | Syqe Medical | US9775379B2 | Method and system for drug delivery | 2010-12-22 | Granted 2017-10-03 (expires 2034-09-26) | Inhaler device for controlled extraction of at least one active substance from at least one type of plant matter by application of heat, including DMT |
46 | 45 | McMaster University | US20130287705A1 | Method Of Treating Mucosal Inflammation | 2010-11-03 | Abandoned | Methods of treating mucosal inflammation in the gastrointestinal tract, by administering 5-HT7 receptor antagonist, including N,N-DMT |
47 | 46 | EaglePharma Pty Ltd | US20130281401A1 | Combination Therapy For The Treatment Of Depression And Other Non-infectious Diseases | 2010-10-07 | Abandoned | Methods of treating a non-infectious disease with combination of methylsulfonylmethane, glucosamine, L-glycine, and vitamin B12, and optionally additional agent, e.g., 5-MeO-DMT |
48 | 47 | Emory University | US20120108510A1 | Methods of improving behavioral therapies | 2010-05-20 | Abandoned | Psychedelic-assisted psychotherapy using an oxytocin releasing agent, including N,N-DMT and 5-MeO-DMT |
49 | 48 | Philip Morris Products | US9974743B2 | Device and method for delivery of a medicament | 2009-09-16 | Granted 2018-05-22 (expires 2034-02-26) | Aerosol delivery devices for inhalation of nicotine, with disclosed uses for other compounds including N,N-DMT and 5-MeO-DMT |
50 | 49 | LTS Lohmann Therapie Systeme GmbH | US10881607B2 | Composition For Transdermal Delivery Of Cationic Active Agents | 2008-06-19 | Granted 2021-01-05 (expires 2029-06-16) | Transdermal patch with composition for transdermal delivery of at least one cationic active agent, including indole compounds such as N,N-DMT |
51 | 50 | Fred Hutchinson Cancer Research Center | WO2009055001A2 | Methods Of Treating Aging And Methods Of Screening Candidate Agents Therefor | 2007-10-23 | Published | Methods of treating aging by administering a 5-HT2 receptor antagonist, including DMT |
52 | 51 | Mark T. Hamann et al. | US8268856B2 | Method To Use Compositions Having Antidepressant Anxiolytic And Other Neurological Activity And Compositions Of Matter | 2007-10-09 | Granted 2012-09-18 (expires 2028-10-09) | Pharmaceutical formulations with antidepressant, anxiolytic, or antiobesity activity isolated from sea sponges, including 5-Bromo-DMT and 5,6-Dibromo-DMT |
53 | 52 | Chelsea Therapeutics Inc | US20130143868A1 | Droxidopa And Pharmaceutical Composition Thereof For The Treatment Of Mood Disorders, Sleep Disorders, Or Attention Deficit Disorders | 2007-05-07 | Abandoned | Methods of treating ADD by administering droxidopa together with a second active agent, including 5-MeO-DMT |
54 | 53 | Philip Morris Products (originally filed by Duke University) | US10668058B2 | Device And Method For Delivery Of A Medicament | 2007-03-30 | Granted 2020-06-02 (expires 2029-02-09) | Aerosol delivery devices for inhalation of nicotine, with disclosed uses for other compounds including N,N-DMT and 5-MeO-DMT |
55 | 54 | Chelsea Therapeutics Inc | US20130116286A1 | Droxidopa And Pharmaceutical Composition Thereof For The Treatment Of Neurally Mediated Hypotension | 2007-03-12 | Abandoned | Methods of treating neurally mediated hypotension by administering droxidopa together with a second active agent, the second agent including 5-MeO-DMT |
56 | 55 | Chelsea Therapeutics Inc | US8008285B2 | Droxidopa And Pharmaceutical Composition Thereof For The Treatment Of Fibromyalgia | 2007-03-09 | Granted 2011-08-30 (expires 2029-02-16) | Methods of treating fibromyalgia by administering droxidopa together with a second active agent, the second agent including 5-MeO-DMT |
57 | 56 | Chien-Hung Chen | US20120183600A1 | Novel Composition For Treating Metabolic Syndrome And Other Conditions | 2007-01-16 | Abandoned | Compositions of an oxidative phosphorylation inhibitor, ionophore, or AMPK activator; an anti-inflammatory agent; and a serotonergic agent, including N,N-DMT and 5-MeO-DMT |
58 | 57 | Lundbeck NA Ltd | US20160106694A1 | Pharmaceutical Compositions Comprising Droxidopa | 2006-06-28 | Abandoned | Pharmaceutical compositions of droxidopa in combination with one or more additional compounds for increasing its half-life, including 5-MeO-DMT |
59 | 58 | Bioniqs Limited | WO2007110637A1 | Method For Extracting Target Alkaloid Using An Ionic Liquid As Extracting Solvent | 2006-03-28 | Published | Methods for extracting a target alkaloid from a mixture of species, by using an ionic liquid as an extracting solvent, including for N,N-DMT and 5-MeO-DMT |
60 | 59 | PLT Patent and License Trading Ltd | US20100143322A1 | Use Of Inhibitors Of N-methyl Transferases For The Therapy Of Parkinson's Disease | 2005-06-24 | Abandoned | Methods for treating Parkinson's with exogenic or endogenic inhibitors of N-methyl transferases, including N,N-DMT |
61 | 60 | Virginia Commonwealth University | US6518297B2 | Selective 5-ht6 Receptor Ligands | 2001-08-20 | Granted 2003-02-11 (expired 2019-12-10) | Treating mental disorders mediated by the 5-HT6 receptor by administering tryptamine derivatives, including 2-ethyl-5-MeO-DMT, and 5-MeO-2-phenyl-N,N-DMT |
62 | 61 | Sigma Tau Industrie Farmaceutiche Riunite SpA | US7098233B2 | 5-halo-tryptamine Derivatives Used As Ligands On The 5-ht6 And/or 5-ht7 Serotonin Receptors | 2001-06-21 | Granted 2006-08-29 (expires 2022-06-17) | Methods of interacting with 5-HT6 and 5-HT7 receptors by administering tryptamine derivatives including 5-bromo-2-methyl- and 5-bromo-2-ethyl-N,N-DMT |
63 | 62 | Psychiatric Genomics Inc | US7132287B2 | Method For Neural Stem Cell Differentiation Using 5ht-1a Agonists | 2001-06-18 | Granted 2006-11-07 (expires 2023-02-23) | Methods for differentiating neural stem cells into a neuronal cell such as a neuroblast or a neuron in vitro or in vivo by contacting with a 5HT1A ligand, including 5-MeO-DMT |
64 | 63 | Alcon Laboratories Inc | WO1998018458A1 | Opthalmological Compositions Containing Serotonin 5-ht1a Receptor Agonist And Their Use In The Treatment Of Glaucoma | 1996-10-31 | Published | Ophthalmic compositions for controlling intraocular pressure with a 5-HT1A receptor agonist that inhibits adenylyl cyclase, including 5-MeO-DMT |
65 | 64 | Nosrat E. Naftchi | US4742054A | Treatment of mammals suffering from damage to the central nervous system | 1982-11-23 | Granted 1988-05-03 (expired 2005-05-03) | Methods for treating a mammal having an injured spinal cord and loss of motor and sensory function by administering a neural receptor agonist, including 5-MeO-DMT |